Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT-I10A + SCT510 vs sorafenib in first-line advanced hepatocellular carcinoma
CTR20201974Phase 3Completed
- Sponsor
- Shenzhou Cell Engineering Co., Ltd.
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of finotonlimab, SCT510A in hepatocellular carcinoma (HCC), sponsored by Shenzhou Cell Engineering Co., Ltd.. Started Oct 2020; status: completed.
02
Drugs
finotonlimabSCT510A
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20201974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201974.